Has Kenneth Baum, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,400 in general payments to Kenneth Baum, MD across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kenneth Baum, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kenneth Baum, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kenneth Baum, MD

Ophthalmology · Honolulu, HINPI 1871692269

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 26.6% of the total. Reporting peaked in 2023 at $1,205 and has fallen 96.7% since, to $39 in 2024.

$3,400in general payments, 2019–2025

Across 57 payments — averaging $59.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$904
NEW World Medical,inc.$707
Alcon$451
Dompe US, Inc.$245
Aerie Pharmaceuticals, Inc.$172
Bausch & Lomb, A Division Of Bausch Health US, LLC$161
plus $761 from 9 others

What the payments were for

Food & beverage$3,400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	22	$904
NEW World Medical,inc.	3	$707
Alcon	6	$451
Dompe US, Inc.	2	$245
Aerie Pharmaceuticals, Inc.	4	$172
Bausch & Lomb, A Division Of Bausch Health US, LLC	4	$161
Glaukos Corporation	1	$150
Sight Sciences, Inc.	1	$148
Ivantis, Inc	2	$128
Rxsight Inc	1	$120
Sun Pharmaceutical Industries Inc.	4	$78
Bausch & Lomb Americas Inc.	3	$62
Amgen(2 entities)	2	$39
Kala Pharmaceuticals, Inc.	1	$19
Novartis	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XEN GLAUCOMA TREATMENT SYSTEM$499
ARGOS$286
Kahook Dual Blade$269
Streamline Surgical System$269
Ahmed Glaucoma Valve$269
enVista MX60 IOL$250
Oxervate$245
iStent inject W$150
OMNI(R) SURGICAL SYSTEM (US)$148
Hydrus Microstent$126
DURYSTA$124
RXSIGHT CONTACT LENS$120
RXSIGHT INJECTOR CARTRIDGE$120
RXSIGHT INJECTOR HANDPIECE$120
RXSIGHT LIGHT DELIVERY DEVICE (LDD)$120
RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$120
Rhopressa$113
Rocklatan$113
Clareon$111

How this compares

$3,400 in reported general payments places this provider in the 55th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii →

Medicare billing

Part B allowed, 2024

$22,545

Medicare patients

Services billed

181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Latanoprost	129	$2,411
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	67	$1,403
Timolol Maleate	66	$1,171
Prednisolone Acetate	31	$1,139
Brimonidine Tartrate	29	$652
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	14	$191

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Honolulu

Neda NikpoorHonolulu$293K
Carlton YuenHonolulu$175K
Alan FaulknerHonolulu$135K
Michael BennettHonolulu$108K
Jeffrey PetersonHonolulu$77K
Rupa WongHonolulu$72K
Jon PortisHonolulu$20K
Tyrie JenkinsHonolulu$19K
John OlkowskiHonolulu$15K
Claudia HootenHonolulu$14K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →